Report Overview

The oral drugs for the rheumatoid arthritis market in the EU are projected to reach USD XX billion by 2028 from USD XX billion in 2019, at a CAGR of 3.11% from 2019 to 2028

Rheumatoid Arthritis usually affects the geriatric population, and the prevalence is seen higher in females as compared to males. There are also several therapeutics and medications that have been developed in recent years, to treat the symptoms of rheumatoid arthritis. Rheumatoid Arthritis treatment is generally lifelong and can require medication changes. No single DMARD(Disease Modifying Anti-Rheumatoid Drugs) is superior as an initial treatment; however, methotrexate is commonly used. In the EU, the increasing number of effective drugs and modes of action (MOAs) has improved the likelihood of reaching the treatment target for individuals with RA, but high drug costs still limit widespread use and thus contribute to inequity of access to best care across various regions in EU



Market Growth Drivers

The key factors propelling the growth of the oral drug for the rheumatoid arthritis treatment market are the new developments in the field of new biosimilars. The rising prevalence of Rheumatoid Arthritis and an increase in the acceptance of biopharmaceuticals will fuel the growth of this market